Insider Sale at Xencor Inc (XNCR): EVP, Chief Development Officer Nancy Valente Sells Shares

9h ago, source:

Nancy Valente, the Executive Vice President, Chief Development Officer of Xencor Inc (NASDAQ:XNCR), sold 4,745 shares of the ...

Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last?

2d ago, source: Zacks.com on MSN

Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Analyst Scoreboard: 6 Ratings For Xencor

17d ago, source: Business Insider

All You Need to Know About Xencor Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and ...

Xencor Appoints Bart Cornelissen as Chief Financial Officer

25d ago, source: Stockhouse

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart ...

Xencor Appoints Bart Cornelissen As CFO

24d ago, source: Business Insider

(RTTNews) - Xencor, Inc. (XNCR), focused on cancer and other serious diseases, on Tuesday announced that it has appointed Bart Cornelissen as chief financial officer. On October 26, 2023 ...

Xencor Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

XNCR Crosses Below Key Moving Average Level

28d ago, source: Nasdaq

In trading on Friday, shares of Xencor, Inc (Symbol: XNCR) crossed below their 200 day moving average of $21.32, changing hands as low as $20.93 per share. Xencor, Inc shares are currently trading ...

Xencor names Bart Cornelissen as new CFO

24d ago, source: Investing

PASADENA, Calif. - Xencor, Inc. (NASDAQ:XNCR), a biopharmaceutical company engaged in the development of engineered antibodies, announced today the appointment of Bart Cornelissen as its new Senior ...

Analyst Scoreboard: 6 Ratings For Xencor

17d ago, source: Benzinga.com

Stay informed and make well-considered decisions with our Ratings Table. Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and ...

Xencor Appoints Bart Cornelissen as Chief Financial Officer

25d ago, source: Morningstar

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of ...